A new dosage strength of the fentanyl transdermal system (Duragesic, Alza) was approved for the management of persistent, moderate-to-severe chronic pain requiring continuous opioid administration for an extended period of time that cannot be managed by other drugs. The new patch will deliver 12 mcg of fentanyl per hour.
A new dosage strength of the fentanyl transdermal system (Duragesic, Alza) was approved for the management of persistent, moderate-to-severe chronic pain requiring continuous opioid administration for an extended period of time that cannot be managed by other drugs. The new patch will deliver 12 mcg of fentanyl per hour.
FDA approved a 40-mg powder for oral suspension formulation of omeprazole (Zegerid, Santarus/Otsuka). The new formulation is indicated for the reduction of risk of upper GI bleeding in critically ill patients and for the short-term treatment (4–8 wk) of active benign gastric ulcers.
FDA approved a new high-potency fluocinonide cream (Vanos, Medicis) for the once- or twice-daily treatment of plaque psoriasis.
FDA granted full approval for doxorubicin liposome injection (Doxil, Tibotec Therapeutics) in the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.
A new aqueous solution formulation of oxaliplatin (Eloxatin, Sanofi-Aventis) was approved for the treatment of colorectal cancer.
FDA approved an intravenous immune globulin (Vaccinia Immune Globulin [VIGIV], Computer Sciences) to treat rare adverse reactions to smallpox vaccination.
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More